Acquisition Opportunity Impact Pharmaceutical Services was acquired by Syner-G in February 2022, indicating potential cross-sell opportunities to Syner-G’s broader client base in biopharma development, regulatory, and commercialization services.

Small Team, Flexible Ops With 2-10 employees, Impact likely benefits from flexible outsourcing and modular partnerships, presenting opportunities for scalable, contract-based services and rapid-response collaborations.

Tech-Driven Fit Existing tech stack elements such as Salesforce, Microsoft Dynamics AX, E-Builder, and collaboration tools align with enterprise-grade partners, suggesting suitability for integrated PM/CRM, regulatory, and project delivery solutions.

Growth Momentum Syner-G’s ongoing expansions and leadership hires, plus recent 3Di AI initiatives, signal a growth trajectory that could open doors for complementary service partnerships, AI-enabled authoring, and knowledge management offerings.

Market Positioning As part of a group with global reach and a focus on drug development lifecycle optimization, there is potential to target mid-market biopharma companies seeking scalable development, regulatory, and commercialization support through Syner-G’s network.